Should I buy or sell Accolade stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks .

What is Accolade's stock price target for 2024?

13 brokers have issued twelve-month price targets for Accolade's stock. Their ACCD share price targets range from $10.00 to $19.00. On average, they expect the company's share price to reach $15.14 in the next year. This suggests a possible upside of 65.7% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts .

How have ACCD shares performed in 2023?

Accolade's stock was trading at $7.79 at the start of the year. Since then, ACCD shares have increased by 17.3% and is now trading at $9.14. View the best growth stocks for 2023 here .

When is Accolade's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, January 8th 2024. View our ACCD earnings forecast .

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) announced its quarterly earnings results on Wednesday, October, 4th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.11. The business earned $96.86 million during the quarter, compared to the consensus estimate of $94.09 million. Accolade had a negative trailing twelve-month return on equity of 30.58% and a negative net margin of 37.24%. The business's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.66) earnings per share.

What ETFs hold Accolade's stock?

ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) , SPDR S&P Health Care Services ETF (XHS) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) . iShares U.S. Healthcare Providers ETF (IHF) .

What guidance has Accolade issued on next quarter's earnings?

Accolade updated its third quarter 2024 earnings guidance on Wednesday, October, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $95.00 million-$97.00 million, compared to the consensus revenue estimate of $96.57 million.

What is Rajeev Singh's approval rating as Accolade's CEO?

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com . Rajeev Singh has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS) , Johnson & Johnson (JNJ) , RTX (RTX) , Alibaba Group (BABA) , Home Depot (HD) , Procter & Gamble (PG) , Thermo Fisher Scientific (TMO) , Cisco Systems (CSCO) and Intel (INTC) .

When did Accolade IPO?

(ACCD) raised $176 million in an initial public offering (IPO) on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

Who are Accolade's major shareholders?

Accolade's stock is owned by many different institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (8.63%), Brown Advisory Inc. (7.96%), ARK Investment Management LLC (7.93%), Rock Springs Capital Management LP (3.82%), Sumitomo Mitsui Trust Holdings Inc. (2.36%) and Northern Trust Corp (0.97%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff. View institutional ownership trends .

How do I buy shares of Accolade?

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Accolade Stock Price, News & Analysis (NASDAQ:ACCD)

$9.14

+0.08 (+0.88%)

(As of 12/4/2023 ET)

Compare

Today's Range: $8.81
▼
$9.20
50-Day Range: $6.50
▼
$10.76
52-Week Range: $6.33
▼
$17.00

Volume: 616,806 shs
Average Volume: 628,072 shs
Market Capitalization: $696.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.14

Accolade MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.69 Rating Score
Upside/Downside: 65.7% Upside
$15.14 Price Target
Short Interest: Healthy
4.11% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.89
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$74,397 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.56) to ($1.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Business Services Sector

37th out of 301 stocks

Business Services, Not Elsewhere Classified Industry

12th out of 85 stocks

4.3

Analyst's Opinion

Consensus Rating
Accolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.14, Accolade has a forecasted upside of 65.7% from its current price of $9.14.
Amount of Analyst Coverage
Accolade has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.11% of the outstanding shares of Accolade have been sold short.
Short Interest Ratio / Days to Cover
Accolade has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Accolade has recently decreased by 2.19%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Accolade does not currently pay a dividend.
Dividend Growth
Accolade does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Accolade has received a 76.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private oncologist's appointments", "Private neurologist's appointments", "Private general practice doctor's diagnostic online appointments", "Private cardiologist's online appointments", and "Private gynaecologist's online appointments" products. See details.
Environmental Sustainability
The Environmental Impact score for Accolade is -0.89.

2.1

News and Social Media Coverage

News Sentiment
Accolade has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Business Services companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Accolade this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for ACCD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,397.00 in company stock.
Percentage Held by Insiders
Only 8.30% of the stock of Accolade is held by insiders.
Percentage Held by Institutions
73.92% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Accolade are expected to grow in the coming year, from ($1.56) to ($1.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Accolade is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Accolade is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Accolade has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Accolade Stock (NASDAQ:ACCD)

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ACCD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACCD Stock News Headlines

December 4, 2023 | americanbankingnews.com

Accolade, Inc. (NASDAQ:ACCD) Receives Consensus Recommendation of "Moderate Buy" from Analysts

November 27, 2023 | finance.yahoo.com

Accolade To Present at Piper Sandler 35th Annual Healthcare Conference

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 22, 2023 | markets.businessinsider.com

Expert Ratings for Accolade

November 16, 2023 | finance.yahoo.com

Accolade Announces Repurchase of $76.5 Million of 0.50% Convertible Senior Notes Due 2026

November 8, 2023 | finance.yahoo.com

Accolade To Present at Stephens Annual Investment Conference

November 5, 2023 | morningstar.com

Accolade Inc Ordinary Shares ACCD

November 2, 2023 | finance.yahoo.com

Down -31.39% in 4 Weeks, Here's Why Accolade (ACCD) Looks Ripe for a Turnaround

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 19, 2023 | msn.com

Accolade: Multiples Should Rerate As ACCD Continues To Execute

October 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Accolade (ACCD)

October 11, 2023 | msn.com

Obesity drug coverage among U.S. employers to nearly double in 2024: survey

October 11, 2023 | markets.businessinsider.com

Cautious Outlook on Accolade’s Future Growth and Valuation: An Analysis of Stan Berenshteyn’s Hold Rating

October 10, 2023 | markets.businessinsider.com

Projected Rise in GLP-1 Coverage by Employers and its Potential Impact on Accolade’s Membership Rates and Health Insurance Costs

October 9, 2023 | msn.com

U.S. employers covering weight-loss drugs could nearly double in 2024 - survey

October 9, 2023 | finance.yahoo.com

GLP-1 Coverage in Employer Plans Could Nearly Double in 2024

October 9, 2023 | finance.yahoo.com

Here's Why Accolade (ACCD) is Poised for a Turnaround After Losing -36.43% in 4 Weeks

October 7, 2023 | msn.com

Why Shares of Accolade Fell This Week

October 5, 2023 | markets.businessinsider.com

Accolade (ACCD) Gets a Buy from D.A. Davidson

October 5, 2023 | markets.businessinsider.com

Raymond James Maintains Outperform Rating for Accolade: Here's What You Need To Know

October 5, 2023 | finanznachrichten.de

Accolade, Inc.: Accolade Announces Results for Fiscal Second Quarter 2024

October 5, 2023 | markets.businessinsider.com

Accolade’s Robust Performance and Steady Financial Outlook: A Comprehensive Analysis for a Buy Rating

October 5, 2023 | finance.yahoo.com

Accolade, Inc. (NASDAQ:ACCD) Q2 2024 Earnings Call Transcript

October 4, 2023 | markets.businessinsider.com

Accolade Announces Results for Fiscal Second Quarter 2024

October 4, 2023 | markets.businessinsider.com

Why Accolade Stock Is Falling After-Hours

October 4, 2023 | finance.yahoo.com

Accolade Inc (ACCD) Reports Strong Q2 2024 Earnings, Exceeds Top and Bottom Line Guidance

October 4, 2023 | msn.com

Levi CEO fires over half of execs, says should have fired “the wrong people” even faster

See More Headlines

Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/04/2023
Today: 12/04/2023
Next Earnings (Estimated): 1/08/2024
Fiscal Year End: 2/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Business services, not elsewhere classified
Sub-Industry: N/A
Sector: Business Services
Current Symbol: NASDAQ:ACCD
CUSIP: N/A
CIK: 1481646
Web: accolade.com
Phone: 206-926-8100
Fax: N/A
Employees: 2,370
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.14
High Stock Price Target: $19.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +65.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.69
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-459,650,000.00
Net Margins: -37.24%
Pretax Margin: -37.19%
Return on Equity: -30.58%
Return on Assets: -15.96%

Debt

Debt-to-Equity Ratio: 0.65
Current Ratio: 3.08
Quick Ratio: 3.08

Sales & Book Value

Annual Sales: $380.06 million
Price / Sales: 1.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.51 per share
Price / Book: 1.40

Miscellaneous

Outstanding Shares: 76,232,000
Free Float: 69,905,000
Market Cap: $696.76 million
Optionable: Not Optionable
Beta: 2.06

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Rajeev Singh (Age 55)
Chairman of the Board & CEO
Comp: $778.5k
Mr. Robert Cavanaugh (Age 54)
President
Comp: $582.63k
Mr. Stephen H. Barnes CPA (Age 51)
CFO & Treasurer
Comp: $557.5k
Ms. Kristen Bruzek
Senior Vice President of Operations
Mr. Colin McHugh (Age 44)
Chief Accounting Officer
Mr. Todd Friedman
Senior Vice President of Investor Relations
Mr. Richard Eskew (Age 48)
Executive VP, General Counsel, CCO & Secretary
Ms. Jennifer Hanson
Executive VP & Chief Human Resource Officer
Mr. Drew Garner
Executive Vice President of Engineering
Dr. Shantanu Nundy M.B.A.
M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Accolade stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares.
View ACCD analyst ratings or view top-rated stocks.
What is Accolade's stock price target for 2024?: 13 brokers have issued twelve-month price targets for Accolade's stock. Their ACCD share price targets range from $10.00 to $19.00. On average, they expect the company's share price to reach $15.14 in the next year. This suggests a possible upside of 65.7% from the stock's current price.
View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts.
How have ACCD shares performed in 2023?: Accolade's stock was trading at $7.79 at the start of the year. Since then, ACCD shares have increased by 17.3% and is now trading at $9.14.
View the best growth stocks for 2023 here.
When is Accolade's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, January 8th 2024.
View our ACCD earnings forecast.
How were Accolade's earnings last quarter?: Accolade, Inc. (NASDAQ:ACCD) announced its quarterly earnings results on Wednesday, October, 4th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.11. The business earned $96.86 million during the quarter, compared to the consensus estimate of $94.09 million. Accolade had a negative trailing twelve-month return on equity of 30.58% and a negative net margin of 37.24%. The business's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.66) earnings per share.
What ETFs hold Accolade's stock?: ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF).

What guidance has Accolade issued on next quarter's earnings?: Accolade updated its third quarter 2024 earnings guidance on Wednesday, October, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $95.00 million-$97.00 million, compared to the consensus revenue estimate of $96.57 million.
What is Rajeev Singh's approval rating as Accolade's CEO?: 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.
What other stocks do shareholders of Accolade own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).
When did Accolade IPO?: (ACCD) raised $176 million in an initial public offering (IPO) on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.
Who are Accolade's major shareholders?: Accolade's stock is owned by many different institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (8.63%), Brown Advisory Inc. (7.96%), ARK Investment Management LLC (7.93%), Rock Springs Capital Management LP (3.82%), Sumitomo Mitsui Trust Holdings Inc. (2.36%) and Northern Trust Corp (0.97%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff.
View institutional ownership trends.
How do I buy shares of Accolade?: Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACCD) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Accolade Stock Price, News & Analysis (NASDAQ:ACCD)

Accolade MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Accolade Stock (NASDAQ:ACCD)

ACCD Stock Price History

ACCD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACCD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™